Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer (Q35569694)

From Wikidata

Jump to navigation Jump to search

scientific article published on 3 May 2011

Language	Label	Description	Also known as
English	Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer	scientific article published on 3 May 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

phase II clinical trial

0 references

0 references

object named as

Larry Norton

12

0 references

Joan Massagué Solé

object named as

Joan Massague

11

0 references

Clifford A Hudis

13

object named as

Clifford Hudis

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

2

object named as

Joseph A Sparano

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

author name string

Ayca Gucalp

1

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

James Caravelli

3

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Jean Santamauro

4

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Sujata Patil

5

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Alyson Abbruzzi

6

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Christine Pellegrino

7

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Jackie Bromberg

8

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Chau Dang

9

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Maria Theodoulou

10

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Tiffany A Traina

14

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

language of work or name

0 references

publication date

3 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Clinical Breast Cancer

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

306-311

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

Latent bone metastasis in breast cancer tied to Src-dependent survival signals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

Src family kinases in tumor progression and metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

12 July 2018

pp60c-src activation in lung adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

26 September 2018

Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

26 September 2018

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3222913

7 December 2018

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21729667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21729667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of c-Src is inversely correlated with biological aggressiveness of breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21729667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.CLBC.2011.03.021

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35569694&oldid=1787861290"